Bioxcel Therapeutics Inc., of New Haven, Conn., said it priced an underwritten public offering of 2.3 million shares of common stock at $8.25 each. The underwriters have been granted a 30-day option to purchase up to an additional 345,454 shares of common stock at the public offering price.